Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data

Wednesday, September 25, 2019 1 min read

Key Takeaway: Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data

Full Press Release Details

Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data.